Features
Dr Emma Harvey, senior medical director at Alexion Pharmaceuticals UK, shares her views on the challenges of working in the field of ultra-...
Spend any time looking into patient adherence and some remarkable figures will come your way: huge losses of money, major pressure placed on...
The industry is poised on the potential widespread adoption of many revolutionary technologies; foremost among them are biosimilars and generics,...
Matt Fellows examines this promising research practice and how it could revamp the pharma R&D landscape.
In the second part of our clinical trials feature, Ben Hargreaves takes take a look at how social media and apps can become...
In the first part of a special double feature, Ben Hargreaves takes a look at how clinical trials are haemorrhaging money...
Mylan’s recent EpiPen price inflation scandal has reignited a seemingly never-ending
debate on the power of drug companies to charge...
The pharmaceutical industry and drug pricing have occupied quite a large space in the debates surrounding the next president of the United States...
The pharmaceutical industry has always taken a keen interest in medical education. With the increased emphasis on transparency with the ABPI’s...
Matt Fellows explores medical and pharmaceutical opinion of the divisive institute to determine whether it is the fit-for-purpose appraisal...
